Cardiovascular Drugs and Therapy最新文献_第10页

Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection. SGLT2抑制剂在急性心力衰竭中的早期启动：关注利尿和肾脏保护。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2023-10-13 DOI: 10.1007/s10557-023-07512-6

Andreas Hammer, Alexander Niessner, Patrick Sulzgruber

{"title":"Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection.","authors":"Andreas Hammer, Alexander Niessner, Patrick Sulzgruber","doi":"10.1007/s10557-023-07512-6","DOIUrl":"10.1007/s10557-023-07512-6","url":null,"abstract":"Purpose: Acute heart failure (AHF) represents a critical and life-threatening condition characterized by the sudden onset or exacerbation of symptoms, such as dyspnea and fluid retention, due to impaired cardiac function. Despite advances in the treatment of chronic heart failure (HF), the management of AHF remains challenging, with limited therapeutic options available. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a promising drug class in AHF management.Methods/results: The objective of this article was to conduct a comprehensive review of the existing literature in the domain of SGLT2 inhibitors and their relevance in the context of AHF.Conclusion: The existing evidence underscores the importance of SGLT2 inhibitors in enhancing decongestive therapy for AHF patients. Early initiation appears both practical and beneficial, leading to improved and sustained decongestion, a reduction in heart failure-related events, enhanced quality of life, and decreased mortality rates, all while maintaining a favorable safety profile. Consequently, it should be considered to initiate SGLT2 inhibitor treatment as early and as safely as possible to facilitate effective decongestion. However, careful patient selection and monitoring are essential when considering the use of these drugs in the management of AHF.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"687-690"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41192189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Approaches Targeting Ferroptosis in Cardiomyopathy. 针对心肌病铁下垂的治疗方法。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2023-11-06 DOI: 10.1007/s10557-023-07514-4

Yanqian Ruan, Ling Zhang, Lina Zhang, Keyang Zhu

引用次数: 0

Metabolism Serves as a Bridge Between Cardiomyocytes and Immune Cells in Cardiovascular Diseases. 代谢是心血管疾病中心肌细胞与免疫细胞之间的桥梁

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2024-01-18 DOI: 10.1007/s10557-024-07545-5

Lixiao Hang, Ying Zhang, Zheng Zhang, Haiqiang Jiang, Lin Xia

{"title":"Metabolism Serves as a Bridge Between Cardiomyocytes and Immune Cells in Cardiovascular Diseases.","authors":"Lixiao Hang, Ying Zhang, Zheng Zhang, Haiqiang Jiang, Lin Xia","doi":"10.1007/s10557-024-07545-5","DOIUrl":"10.1007/s10557-024-07545-5","url":null,"abstract":"Metabolic disorders of cardiomyocytes play an important role in the progression of various cardiovascular diseases. Metabolic reprogramming can provide ATP to cardiomyocytes and protect them during diseases, but this transformation also leads to adverse consequences such as oxidative stress, mitochondrial dysfunction, and eventually aggravates myocardial injury. Moreover, abnormal accumulation of metabolites induced by metabolic reprogramming of cardiomyocytes alters the cardiac microenvironment and affects the metabolism of immune cells. Immunometabolism, as a research hotspot, is involved in regulating the phenotype and function of immune cells. After myocardial injury, both cardiac resident immune cells and heart-infiltrating immune cells significantly contribute to the inflammation, repair and remodeling of the heart. In addition, metabolites generated by the metabolic reprogramming of immune cells can further affect the microenvironment, thereby affecting the function of cardiomyocytes and other immune cells. Therefore, metabolic reprogramming and abnormal metabolite levels may serve as a bridge between cardiomyocytes and immune cells, leading to the development of cardiovascular diseases. Herein, we summarize the metabolic relationship between cardiomyocytes and immune cells in cardiovascular diseases, and the effect on cardiac injury, which could be therapeutic strategy for cardiovascular diseases, especially in drug research.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"661-676"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the Editor Regarding the SELECT Trial. 致编辑关于SELECT试验的信。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-02 DOI: 10.1007/s10557-025-07686-1

Michail Penteris, Konstantinos Lampropoulos

引用次数: 0

Post-TEVAR Type A Aortic Dissection: Insights and Future Directions. tevar后A型主动脉夹层：见解和未来方向。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-08 DOI: 10.1007/s10557-025-07681-6

Jessica K Wang, Xander H T Wehrens, K Jane Grande-Allen

引用次数: 0

GLP-1 Receptor Agonists and Cardiac Health: Insights from a Systematic Review. GLP-1受体激动剂与心脏健康：来自系统综述的见解。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-15 DOI: 10.1007/s10557-025-07680-7

Mauricio Reis Pedrosa, Arnaldo Alves da Silva, Virginia Fernandes Moça Trevisani

引用次数: 0

MOTS-c: Magical Molecule for Diabetic Cardiomyopathy? MOTS-c：治疗糖尿病心肌病的神奇分子？

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-02 DOI: 10.1007/s10557-025-07689-y

Veera Ganesh Yerra, Kim A Connelly

引用次数: 0

Interplay Between TGF-β Signaling and MicroRNA in Diabetic Cardiomyopathy. 糖尿病心肌病中 TGF-β 信号与 MicroRNA 之间的相互作用

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2023-12-20 DOI: 10.1007/s10557-023-07532-2

Jianning Qin, Yao Tan, Yang Han, Letian Yu, Shali Liu, Simin Zhao, Hengquan Wan, Shunlin Qu

引用次数: 0

Comparison Between Drug-Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis of RCT Data. 大面积新发冠状动脉疾病中药物涂层球囊与支架的比较：一项系统性回顾和 RCT 数据的 Meta 分析。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2024-01-25 DOI: 10.1007/s10557-024-07548-2

Zhiqiang Ma, Kanling Liu, Yanhui Hu, Xiwen Hu, Binyu Wang, Zhengyi Li

{"title":"Comparison Between Drug-Coated Balloon and Stents in Large De Novo Coronary Artery Disease: A Systematic Review and Meta-Analysis of RCT Data.","authors":"Zhiqiang Ma, Kanling Liu, Yanhui Hu, Xiwen Hu, Binyu Wang, Zhengyi Li","doi":"10.1007/s10557-024-07548-2","DOIUrl":"10.1007/s10557-024-07548-2","url":null,"abstract":"Purpose: Although a number of studies involving small-vessel de novo coronary disease showed clinical benefits of drug-coated balloons (DCB), the role of DCB in large vessel lesions is still unclear.Methods: We searched main electronic databases for randomized controlled trials (RCTs) comparing DCB with stents for large vessel de novo coronary artery disease. The primary endpoint was major cardiovascular adverse events (MACE), composite cardiovascular death (CD), myocardial infarction (MI), or target lesion revascularization (TLR).Results: This study included 7 RCTs with 770 participants. DCB were associated with a marked risk reduction in MACE [Risk Ratio (RR): 0.48; 95% confidence interval [CI]: 0.24 to 0.97; P = 0.04], TLR (RR: 0.53; 95% CI: 0.25 to 1.14; P = 0.10), and late lumen loss [standard mean difference (SMD): -0.57; 95% CI: -1.09 to -0.05; P = 0.03] as compared with stents. There is no significant difference in MI (RR: 0.58; 95% CI: 0.21 to 1.54; P = 0.27), CD (RR: 0.33; 95% CI: 0.06 to 1.78; P = 0.19), and minimal lumen diameter (SMD: -0.34; 95% CI: -0.72 to 0.05; P = 0.08) between groups. In subgroup analyses, the risk reduction of MACE persisted in patients with chronic coronary syndrome (RR: 0.25; 95% CI: 0.07 to 0.89; P = 0.03), and patients receiving DCB vs. bare metal stent (RR: 0.19; 95% CI: 0.05 to 0.73; P = 0.01). In addition, there was no significant difference between the DCB group and the drug eluting stent group for MACE (RR: 0.69; 95% CI: 0.30 to 1.60; P = 0.38).Conclusion: DCB may be an effective therapeutic option in patients with large vessel de novo coronary artery disease.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"677-686"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12116820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Toll-like Receptor-2/4 Antagonist, Sparstolonin B, and Inflammatory Diseases: A Literature Mining and Network Analysis. Toll样受体-2/4拮抗剂Sparstolonin B与炎症性疾病：文献挖掘与网络分析》。

IF 3.1 3区医学

Cardiovascular Drugs and Therapy Pub Date : 2025-06-01 Epub Date: 2024-01-25 DOI: 10.1007/s10557-023-07535-z

Rongyuan Yang, Qingqing Liu, Dawei Wang, Zhen Zhao, Zhaohai Su, Daping Fan, Qing Liu

{"title":"The Toll-like Receptor-2/4 Antagonist, Sparstolonin B, and Inflammatory Diseases: A Literature Mining and Network Analysis.","authors":"Rongyuan Yang, Qingqing Liu, Dawei Wang, Zhen Zhao, Zhaohai Su, Daping Fan, Qing Liu","doi":"10.1007/s10557-023-07535-z","DOIUrl":"10.1007/s10557-023-07535-z","url":null,"abstract":"Background: Sparstolonin B (SsnB) is characterized as a new toll-like receptor (TLR)-2/4 antagonist. However, the effects of SsnB on different inflammatory diseases have not been systemically reviewed.Methods: We investigated the effects of SsnB on inflammatory diseases with data mining and network analysis of literature, including frequency description, cluster analysis, association rule mining, functional enrichment, and protein-protein interaction (PPI) mining.Results: A total of 27 experimental reports were included. The ARRIVE 2.0 guidelines were used to evaluate the quality of animal studies. Frequency analysis revealed 13 different diseases (cardio-cerebrovascular system diseases account for 23.53%), 12 pharmacological effects (anti-inflammatory effect accounts for 53.85%), and 67 therapeutic targets. The overview of investigation sequence of SsnB studies was depicted by Sankey diagram. Cluster analysis classified the therapeutic targets for SsnB into four main categories: (1) NF-κB; (2) IL-1β, IL-6, and TNF-α; (3) TLR2, TLR4, and MyD88; (4) the other targets. Moreover, the Apriori association discovered two main association pairs: (1) TNF-α, IL-1β, and IL-6 and (2) TLR2, TLR4, and MyD88 (support range 33.33-50%, confidence range 83.33-88.89%). Functional enrichment of the therapeutic targets for SsnB showed that the top enriched items in the biological process were mainly the response to lipopolysaccharide (LPS)/bacterial origin and regulation of cytokine production. Finally, the PPI network and hub gene selection by maximal clique centrality (MCC) algorithm indicated the top ranked proteins were TNF-α, IL-1β, IL-6, AKT1, PPAR-γ, TLR4, CCL2, and TLR2.Conclusion: These results emphasized the importance of TLR2/TLR4-MyD88-NF-κB-IL-1β/IL-6/TNF-α pathways as therapeutic targets of SsnB in inflammatory diseases.","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"499-515"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0